Back to Search
Start Over
Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Oct 04; Vol. 12, pp. 727850. Date of Electronic Publication: 2021 Oct 04 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global pandemic we are facing. Immunocompromised patients represent a vulnerable population at high risk of developing severe COVID-19 and thus should be prioritized in the vaccination programs and in the study of the vaccine efficacy. Nevertheless, most data on efficacy and safety of the available vaccines derive from trials conducted on healthy individuals; hence, studies on immunogenicity of SARS-CoV2 vaccines in such populations are deeply needed. Here, we perform an observational longitudinal study analyzing the humoral and cellular response following the BNT162b2 mRNA COVID-19 vaccine in a cohort of patients affected by inborn errors of immunity (IEI) compared to healthy controls (HC). We show that both IEI and HC groups experienced a significant increase in anti-SARS-CoV-2 Abs 1 week after the second scheduled dose as well as an overall statistically significant expansion of the Ag-specific CD4+CD40L+ T cells in both HC and IEI. Five IEI patients did not develop any specific CD4+CD40L+ T cellular response, with one of these patients unable to also mount any humoral response. These data raise immunologic concerns about using Ab response as a sole metric of protective immunity following vaccination for SARS-CoV-2. Taken together, these findings suggest that evaluation of vaccine-induced immunity in this subpopulation should also include quantification of Ag-specific T cells.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Amodio, Ruggiero, Sgrulletti, Pighi, Cotugno, Medri, Morrocchi, Colagrossi, Russo, Zaffina, Di Matteo, Cifaldi, Di Cesare, Rivalta, Pacillo, Santilli, Giancotta, Manno, Ciofi Degli Atti, Raponi, Rossi, Finocchi, Cancrini, Perno, Moschese and Palma.)
- Subjects :
- Adolescent
Adult
Antibodies, Neutralizing blood
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
BNT162 Vaccine
CD4 Lymphocyte Count
COVID-19 prevention & control
Female
Humans
Immunity, Cellular immunology
Immunity, Humoral immunology
Immunocompromised Host immunology
Longitudinal Studies
Male
Middle Aged
Vaccination
Young Adult
Antibodies, Viral blood
CD4-Positive T-Lymphocytes immunology
COVID-19 Vaccines immunology
Immunogenicity, Vaccine immunology
Primary Immunodeficiency Diseases immunology
SARS-CoV-2 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34671350
- Full Text :
- https://doi.org/10.3389/fimmu.2021.727850